Furthermore, ANXA2 can activate the Vγ8Vδ3 T cell receptors specifically and is identified and targeted as an antigen by the FMS-01 monoclonal antibody, which specifically inhibits Vγ8Vδ3 TCR-mediated recognition of GBM cells31. Here, ANXA2 is linked to glioblastoma.